Indication intelligence, analysis and sector perception

RegMed Investors (RMi) Research Note: Q1/23 earnings reporting dates, net losses, cash positions and runway outcomes

May 27, 2023

LPS (loss-per-share) releases will present challenges to share pricing with outcomes included 35 reported to date with one 1 net income (VYGR) ... <read more>   Mesoblast (MESO) 3/25 - Friday        

UniQure NV (QURE) to sell royalty interest in blood disorder therapy for up to $400 M

May 15, 2023

QURE (+$0.11) will sell a part of the royalty rights for the world's most expensive treatment Hemgenix to HealthCare Royalty and Sagard Healthcare.

RegMed Investors (RMi) Research Note: Q4 and FY22 earnings reporting

April 10, 2023

The cell and gene therapy sector fluctuates in revenues, collaboration, regulatory submissions and expenses, but the changes may alarm investors who prefer to see expectation and consensus stability and share pricing growth. Stock pricing rises or falls before and after an earnings announcement, depending on whether the earnings meet or fall short of expectations. To date … 31 of 35 (adding BLUE, BCLI, ADVM OTCQB: BSTG)